Company Skye Bioscience, Inc. Other OTC
Equities
SKYE
US83086J1016
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Punit Dhillon
CEO | Chief Executive Officer | 44 | 18/01/18 |
Director of Finance/CFO | - | 04/10/21 | |
Chief Tech/Sci/R&D Officer | 52 | 12/12/22 | |
Karam Takhar
IRC | Investor Relations Contact | - | - |
Rhea Williams
LAW | General Counsel | - | 06/10/21 |
Tu Diep
PRN | Corporate Officer/Principal | 43 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 06/08/20 | |
Praveen Tyle
BRD | Director/Board Member | 64 | 21/07/21 |
Andrew Schwab
BRD | Director/Board Member | 53 | 17/08/23 |
Paul Grayson
BRD | Director/Board Member | - | 17/08/23 |
Punit Dhillon
CEO | Chief Executive Officer | 44 | 18/01/18 |
Keith Ward
BRD | Director/Board Member | 54 | 13/12/21 |
Deborah Charych
BRD | Director/Board Member | - | 13/02/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,067,907 | 27,452,119 ( 97.81 %) | 0 | 97.81 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |